dalteparin has been researched along with Respiratory Distress Syndrome in 8 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "She was diagnosed with a large pulmonary embolism and was hemodynamically unstable therefore requiring endotracheal intubation and norepinephrine support." | 5.56 | Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient. ( Bornstein, G; Zornitzki, L, 2020) |
| "SARS-CoV-2 patients with acute respiratory distress syndrome show elevated fibrinogen activity, high D-dimer levels and maximum amplitude of clot strength." | 3.96 | Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study. ( Antonelli, M; Biasucci, DG; Bocci, MG; Carelli, S; Consalvo, LM; Cutuli, SL; De Candia, E; Franceschi, F; Gori, C; Grieco, DL; Maviglia, R; Mercurio, G; Montini, L; Nardi, G; Natalini, D; Pisapia, L; Rosenkranz, R, 2020) |
| "Despite standard thromboprophylaxis, venous thrombosis is common in critically ill patients with COVID-19." | 1.72 | [Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis]. ( Bonelli, I; Hunter, M; López Saubidet, I; Lurbet, MF; Mandó, F; Parodi, J; Rodríguez, PO, 2022) |
| "She was diagnosed with a large pulmonary embolism and was hemodynamically unstable therefore requiring endotracheal intubation and norepinephrine support." | 1.56 | Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient. ( Bornstein, G; Zornitzki, L, 2020) |
| "A 43-year-old white woman with adult respiratory distress syndrome developed localized dermal necrosis and thrombocytopenia secondary to subcutaneous administration of unfractionated heparin." | 1.30 | Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. ( Kollef, MH; Schaiff, RA; Tonn, ME, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marini, CP | 1 |
| Lewis, E | 1 |
| Petrone, P | 1 |
| Zenilman, A | 1 |
| Lu, Z | 1 |
| Rivera, A | 1 |
| McNelis, J | 1 |
| Hunter, M | 1 |
| Lurbet, MF | 1 |
| Parodi, J | 1 |
| Mandó, F | 1 |
| Bonelli, I | 1 |
| Rodríguez, PO | 1 |
| López Saubidet, I | 1 |
| Massabeti, R | 1 |
| Cipriani, MS | 1 |
| Valenti, I | 1 |
| Zornitzki, L | 1 |
| Bornstein, G | 1 |
| Bocci, MG | 1 |
| Maviglia, R | 1 |
| Consalvo, LM | 1 |
| Grieco, DL | 1 |
| Montini, L | 1 |
| Mercurio, G | 1 |
| Nardi, G | 1 |
| Pisapia, L | 1 |
| Cutuli, SL | 1 |
| Biasucci, DG | 1 |
| Gori, C | 1 |
| Rosenkranz, R | 1 |
| De Candia, E | 1 |
| Carelli, S | 1 |
| Natalini, D | 1 |
| Antonelli, M | 1 |
| Franceschi, F | 1 |
| Sukhdeo, S | 1 |
| Negroponte, E | 1 |
| Rajasekhar, H | 1 |
| Gaur, S | 1 |
| Horton, DB | 1 |
| Malhotra, A | 1 |
| Moorthy, LN | 1 |
| Hanify, JM | 1 |
| Dupree, LH | 1 |
| Johnson, DW | 1 |
| Ferreira, JA | 1 |
| Tonn, ME | 1 |
| Schaiff, RA | 1 |
| Kollef, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)[NCT04406389] | Phase 4 | 14 participants (Actual) | Interventional | 2020-10-13 | Terminated (stopped due to Low accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm (NCT04406389)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intermediate Dose Prophylaxis | 0 |
| Therapeutic Dose Anticoagulation | 2 |
Comparison of length of ICU stay in days between each treatment arm. (NCT04406389)
Timeframe: 6 months
| Intervention | Days (Median) |
|---|---|
| Intermediate Dose Prophylaxis | 25.5 |
| Therapeutic Dose Anticoagulation | 25 |
Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | ||
|---|---|---|---|
| Venous Thromboembolism Events | Arterial Thrombosis Events | Microthrombosis Events | |
| Intermediate Dose Prophylaxis | 1 | 1 | 0 |
| Therapeutic Dose Anticoagulation | 0 | 0 | 1 |
Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria. (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | |
|---|---|---|
| Major Bleeding Events | Clinically Relevant Non-Major Bleeding Events | |
| Intermediate Dose Prophylaxis | 1 | 1 |
| Therapeutic Dose Anticoagulation | 1 | 2 |
8 other studies available for dalteparin and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Incidence; Male; Middle Aged; Pul | 2022 |
[Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis].
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Humans; Incidence; Respiratory Distre | 2022 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infecti | 2020 |
Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient.
Topics: Aged, 80 and over; Anticoagulants; Ceftriaxone; Enoxaparin; Female; Furosemide; Humans; Pulmonary Em | 2020 |
Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation Disorders; Blood Coagulati | 2020 |
Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Topics: Antiviral Agents; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cy | 2021 |
Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Heparin; Hospitalization; Humans; Incide | 2017 |
Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies.
Topics: Adult; Antibodies; Anticoagulants; Cross Reactions; Drug Eruptions; Enoxaparin; Female; Heparin; Hum | 1997 |